← Tyra Biosciences, Inc. (TYRA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Tyra Biosciences, Inc. (TYRA)
Pharmaceutical Preparations · market cap $1.4B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Tyra Biosciences (TYRA) is a ~$1.9B market-cap clinical-stage pharmaceutical company with 60 employees, built around its lead asset TYRA-300 (dabogratinib), a selective FGFR inhibitor in Phase 2 trials across low-grade non-muscle-invasive bladder cancer (NMIBC), locally advanced urothelial carcinoma, low-grade upper tract urothelial carcinoma, and achondroplasia. The company holds $85M in cash against an estimated 7.8-month runway, with a key Phase 2 readout for TYRA-300 expected around November 2026.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| TYRA-300 60mg | Phase 2 | Low-grade NMIBC |
| TYRA-300 | Phase 2 | Locally Advanced Urothelial Carcinoma |
| TYRA-300 0.125 mg/kg | Phase 2 | Achondroplasia |
| Dabogratinib (TYRA-300) 60mg | Phase 2 | Low Grade Upper Tract Urothelial Carcinoma |
Price & technical context
3-month
-31.4%
6-month
-45.1%
12-month
+50.2%
52-wk range
$13.37–$39.61
vs 50-day MA
-19.5%
vs 200-day MA
-31.1%
Realized vol
67.7%
Max drawdown
-75.3%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TYRA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.